Cargando…

Characterization of [(11)C]Lu AE92686 as a PET radioligand for phosphodiesterase 10A in the nonhuman primate brain

PURPOSE: [(11)C]Lu AE92686 is a positron emission tomography (PET) radioligand that has recently been validated for examining phosphodiesterase 10A (PDE10A) in the human striatum. [(11)C]Lu AE92686 has high affinity for PDE10A (IC (50) = 0.39 nM) and may also be suitable for examination of the subst...

Descripción completa

Detalles Bibliográficos
Autores principales:	Yang, Kai-Chun, Stepanov, Vladimir, Amini, Nahid, Martinsson, Stefan, Takano, Akihiro, Nielsen, Jacob, Bundgaard, Christoffer, Bang-Andersen, Benny, Grimwood, Sarah, Halldin, Christer, Farde, Lars, Finnema, Sjoerd J.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Berlin Heidelberg 2016
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5215309/ https://www.ncbi.nlm.nih.gov/pubmed/27817159 http://dx.doi.org/10.1007/s00259-016-3544-9

Ejemplares similares

Neurokinin-3 Receptor Binding in Guinea Pig, Monkey, and Human Brain: In Vitro and in Vivo Imaging Using the Novel Radioligand, [(18)F]Lu AF10628
por: Varnäs, Katarina, et al.
Publicado: (2016)

Fenfluramine Reduces [(11)C]Cimbi-36 Binding to the 5-HT(2A) Receptor in the Nonhuman Primate Brain
por: Yang, Kai-Chun, et al.
Publicado: (2017)

Large Variation in Brain Exposure of Reference CNS Drugs: a PET Study in Nonhuman Primates
por: Schou, Magnus, et al.
Publicado: (2015)

Effects of sevoflurane anaesthesia on radioligand binding to monoamine oxidase-B in vivo
por: Varnäs, Katarina, et al.
Publicado: (2021)

Serotonin concentration enhancers at clinically relevant doses reduce [(11)C]AZ10419369 binding to the 5-HT(1B) receptors in the nonhuman primate brain
por: Yang, Kai-Chun, et al.
Publicado: (2018)

Application of cross-species PET imaging to assess neurotransmitter release in brain
por: Finnema, Sjoerd J., et al.
Publicado: (2015)

PET Evaluation of the Novel F-18 Labeled Reversible Radioligand [(18)F]GEH200449 for Detection of Monoamine Oxidase-B in the Non-Human Primate Brain
por: Varnäs, Katarina, et al.
Publicado: (2023)

Synthesis, Biodistribution, and Radiation Dosimetry of a Novel mGluR5 Radioligand: (18)F-AZD9272
por: Nag, Sangram, et al.
Publicado: (2020)

ABC transporter-dependent brain uptake of the 5-HT(1B) receptor radioligand [(11)C]AZ10419369: a comparative PET study in mouse, rat, and guinea pig
por: Tóth, Miklós, et al.
Publicado: (2014)

Characterization of a Novel M4 PAM PET Radioligand [11C]PF06885190 in Nonhuman Primates (NHP)
por: Nag, Sangram, et al.
Publicado: (2023)

Synthesis and Autoradiography of Novel F-18 Labeled Reversible Radioligands for Detection of Monoamine Oxidase B
por: Nag, Sangram, et al.
Publicado: (2020)

[(11)C]MADAM Used as a Model for Understanding the Radiometabolism of Diphenyl Sulfide Radioligands for Positron Emission Tomography (PET)
por: Gourand, Fabienne, et al.
Publicado: (2015)

PET Imaging of VMAT2 with the Novel Radioligand [(18)F]FE-DTBZ-d4 in Nonhuman Primates: Comparison with [(11)C]DTBZ and [(18)F]FE-DTBZ
por: Nag, Sangram, et al.
Publicado: (2021)

Potential for imaging the high-affinity state of the 5-HT(1B) receptor: a comparison of three PET radioligands with differing intrinsic activity
por: Lindberg, Anton, et al.
Publicado: (2019)

Synthesis and evaluation of 2-chloro N-[(S)-{(S)-1-[(11) C]methylpiperidin-2-yl} (phenyl)methyl]3-trifluoromethyl-benzamide ([(11) C]N-methyl-SSR504734) as a PET radioligand for glycine transporter 1
por: Fuchigami, Takeshi, et al.
Publicado: (2012)

“In‐loop” carbonylation—A simplified method for carbon‐11 labelling of drugs and radioligands
por: Ferrat, Mélodie, et al.
Publicado: (2020)

Kinetic analysis and test-retest variability of the radioligand [(11)C](R)-PK11195 binding to TSPO in the human brain - a PET study in control subjects
por: Jučaite, Aurelija, et al.
Publicado: (2012)

Microsome Mediated in Vitro Metabolism: A Convenient Method for the Preparation of the PET Radioligand Metabolite [(18)F]FE-PE2I-OH for Translational Dopamine Transporter Imaging
por: Schou, Magnus, et al.
Publicado: (2023)

Amphetamine Decreases α(2C)-Adrenoceptor Binding of [(11)C]ORM-13070: A PET Study in the Primate Brain
por: Finnema, Sjoerd J, et al.
Publicado: (2015)

Hematotoxicity and Nephrotoxicity in Prostate Cancer Patients Undergoing Radioligand Therapy with [(177)Lu]Lu-PSMA I&T
por: Hartrampf, Philipp E., et al.
Publicado: (2022)

Comparison of different methods for post-therapeutic dosimetry in [(177)Lu]Lu-PSMA-617 radioligand therapy
por: Rosar, Florian, et al.
Publicado: (2021)

Renal Safety of [(177)Lu]Lu-PSMA-617 Radioligand Therapy in Patients with Compromised Baseline Kidney Function
por: Rosar, Florian, et al.
Publicado: (2021)

The development of a GPR44 targeting radioligand [(11)C]AZ12204657 for in vivo assessment of beta cell mass
por: Jahan, Mahabuba, et al.
Publicado: (2018)

Serotonin and Norepinephrine Transporter Occupancy of Tramadol in Nonhuman Primate Using Positron Emission Tomography
por: Arakawa, Ryosuke, et al.
Publicado: (2018)

Radioligand therapy using [(177)Lu]Lu-PSMA-617 in mCRPC: a pre-VISION single-center analysis
por: Seifert, Robert, et al.
Publicado: (2020)

(177)Lu-PSMA radioligand therapy of predominant lymph node metastatic prostate cancer
por: von Eyben, Finn Edler, et al.
Publicado: (2019)

Lutathera(®) Orphans: State of the Art and Future Application of Radioligand Therapy with (177)Lu-DOTATATE
por: Urso, Luca, et al.
Publicado: (2023)

Predictors of overall survival in metastatic castration-resistant prostate cancer patients receiving [(177)Lu]Lu-PSMA-617 radioligand therapy
por: Ahmadzadehfar, Hojjat, et al.
Publicado: (2017)

Preclinical investigations using [(177)Lu]Lu-Ibu-DAB-PSMA toward its clinical translation for radioligand therapy of prostate cancer
por: Tschan, Viviane J., et al.
Publicado: (2022)

RadioLigand Therapy with [(177)Lu]Lu-PSMA-617 for Salivary Gland Cancers: Literature Review and First Compassionate Use in France
por: Terroir, Marie, et al.
Publicado: (2023)

Joint EANM/SNMMI procedure guideline for the use of (177)Lu-labeled PSMA-targeted radioligand-therapy ((177)Lu-PSMA-RLT)
por: Kratochwil, Clemens, et al.
Publicado: (2023)

Streamlined Schemes for Dosimetry of (177)Lu-Labeled PSMA Targeting Radioligands in Therapy of Prostate Cancer
por: Kurth, Jens, et al.
Publicado: (2021)

Intermittent Radioligand Therapy with (177)Lu-PSMA-617 for Oligometastatic Castration-Resistant Prostate Cancer
por: Mader, Nicolai, et al.
Publicado: (2023)

Response to [(177)Lu]Lu-PSMA radioligand therapy in metastatic castration-resistant prostate cancer patients presenting with only lymph node metastases
por: Zisser, Lucia, et al.
Publicado: (2022)

Impact of [(177)Lu]Lu-PSMA-617 Radioligand Therapy on Reference Organ Uptake Assessed by [(68)Ga]Ga-PSMA-11-PET/CT
por: Groener, Daniel, et al.
Publicado: (2023)

(177)Lu-PSMA-617 radioligand therapy for a patient with lymph node metastatic prostate cancer
por: von Eyben, Finn E., et al.
Publicado: (2017)

[(18)F]FE-PE2I DAT correlates with Parkinson’s disease duration, stage, and rigidity/bradykinesia scores: a PET radioligand validation study
por: Kerstens, Vera S., et al.
Publicado: (2023)

Novel Radioligands for Cyclic Nucleotide Phosphodiesterase Imaging with Positron Emission Tomography: An Update on Developments Since 2012
por: Schröder, Susann, et al.
Publicado: (2016)

Serotonin transporter occupancy with TCAs and SSRIs: a PET study in patients with major depressive disorder
por: Lundberg, Johan, et al.
Publicado: (2012)

Factors predicting biochemical response and survival benefits following radioligand therapy with [(177)Lu]Lu-PSMA in metastatic castrate-resistant prostate cancer: a review
por: Manafi-Farid, Reyhaneh, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_vb13isg0rn7769vdrbuau9dufg